Literature DB >> 2940971

Ciprofloxacin concentrations in bone and muscle after oral dosing.

I W Fong, W H Ledbetter, A C Vandenbroucke, M Simbul, V Rahm.   

Abstract

Ciprofloxacin, a quinoline derivative with marked gram-negative and staphylococcal activity, may be a valuable orally administered agent for use against soft-tissue and bone infections. The concentrations of this antibiotic in serum, bone, and muscle samples were determined in patients undergoing orthopedic surgery. A total of 18 patients undergoing hip or knee replacement surgery or osteotomy were randomized to receive single oral doses of ciprofloxacin (500 mg, 750 mg, or 1 g); 10 patients with osteomyelitis were given single doses of 500 or 750 mg. Mean levels in bone of more than 1 microgram/g were achieved with the 750-mg ciprofloxacin doses in patients with osteomyelitis (1.4 +/- 1 microgram/g) or with the 1-g doses in patients without infections (1.6 +/- 0.6 microgram/g). The levels in muscle were significantly higher with each increasing dose level. Orally administered ciprofloxacin (750 mg given every 12 h) should provide adequate concentrations in bones and soft tissues to treat most osteomyelitis and soft-tissue infections.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2940971      PMCID: PMC180403          DOI: 10.1128/AAC.29.3.405

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Antibiotics in acute osteomyelitis in children.

Authors:  N J Blockey; T A McAllister
Journal:  J Bone Joint Surg Br       Date:  1972-05

2.  Experimental osteomyelitis. II. Therapeutic trials and measurement of antibiotic levels in bone.

Authors:  C W Norden
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

Review 3.  Determination of hemoglobin and its derivatives.

Authors:  E J Van Kampen; W G Zijlstra
Journal:  Adv Clin Chem       Date:  1965       Impact factor: 5.394

4.  Clindamycin treatment of osteomyelitis and septic arthritis in children.

Authors:  R D Feigin; L K Pickering; D Anderson; R E Keeney; P G Shackleford
Journal:  Pediatrics       Date:  1975-02       Impact factor: 7.124

5.  Further observations on the value of oral penicillins in chronic staphylococcal osteomyelitis.

Authors:  S M Bell
Journal:  Med J Aust       Date:  1976-10-16       Impact factor: 7.738

6.  Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.

Authors:  J A Hoogkamp-Korstanje
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

7.  Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.

Authors:  W Wingender; K H Graefe; W Gau; D Förster; D Beermann; P Schacht
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

8.  Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

Authors:  C C Sanders; W E Sanders; R V Goering; V Werner
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

9.  Pharmacokinetics of ciprofloxacin after oral and parenteral administration.

Authors:  G Höffken; H Lode; C Prinzing; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

10.  Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa.

Authors:  C W Norden; E Shinners
Journal:  J Infect Dis       Date:  1985-02       Impact factor: 5.226

View more
  35 in total

1.  Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients.

Authors:  M Müller; M Brunner; U Hollenstein; C Joukhadar; R Schmid; E Minar; H Ehringer; H G Eichler
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 2.  Clinical role of protein binding of quinolones.

Authors:  Eugénie Bergogne-Bérézin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

Review 4.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

Review 5.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

Review 6.  Total hip arthroplasty infection caused by an unusual organism, Salmonella; its successful management and literature review.

Authors:  Chetan Muralidhara Rao Dojode; Jessica Stephens Hemingway; Puthur Damodaran; Nirav N Shah
Journal:  BMJ Case Rep       Date:  2018-06-27

7.  Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis.

Authors:  P Dellamonica; E Bernard; H Etesse; R Garraffo; H B Drugeon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

8.  Inappropriate breast secretions of possible bacterial etiology in the parous nonpuerperal female.

Authors:  J J Freeman; R H Altieri; A H Freeman; T Kuo; F Sardinha; C C Buckingham; J J Sklar; K Dyroff; A Floyd
Journal:  J Natl Med Assoc       Date:  1994-03       Impact factor: 1.798

9.  Concentrations of ticarcillin and clavulanic acid in human bone after prophylactic administration of 5.2 g of timentin.

Authors:  D Adam; H D Heilmann; K Weismeier
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

Review 10.  Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.

Authors:  Nikolas J Onufrak; Alan Forrest; Daniel Gonzalez
Journal:  Clin Ther       Date:  2016-07-20       Impact factor: 3.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.